Positions

Selected Publications

Academic Article

Year Title Altmetric
2020 Implantable system for treprostinil: a real-world patient experience study 2020
2019 Long-term results of the DelIVery for Pulmonary Arterial Hypertension trial 2019
2018 Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe? 2018
2017 Totally Implantable IV Treprostinil Therapy in Pulmonary Hypertension Assessment of the Implantation Procedure 2017
2017 Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction 2017
2017 Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure—does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS) 2017
2017 Remote haemodynamic-guided care for patients with chronic heart failure: a meta-analysis of completed trials 2017
2017 Intracardiac Pressures Measured Using an Implantable Hemodynamic Monitor: Relationship to Mortality in Patients with Chronic Heart Failure 2017
2017 Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus document 2017
2016 Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS 2016
2016 An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension 2016
2016 Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System: Results of the DelIVery for PAH Trial 2016
2016 Pulmonary Artery Pressure-Guided Heart Failure Management Reduces 30-Day Readmissions 2016
2016 Interventions Linked to Decreased Heart Failure Hospitalizations During Ambulatory Pulmonary Artery Pressure Monitoring 2016
2016 Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: Complete follow-up results from the CHAMPION randomised trial 2016
2015 Acute heart failure in the elderly: Differences in clinical characteristics, outcomes, and prognostic factors in the Veritas study 2015
2015 Heart failure and respiratory hospitalizations are reduced in patients with heart failure and chronic obstructive pulmonary disease with the use of an implantable pulmonary artery pressure monitoring device 2015
2015 Pulmonary hypertension related to left heart disease: Insight from a wireless implantable hemodynamic monitor 2015
2015 The reply 2015
2014 Worsening heart failure, a critical event during hospital admission for acute heart failure: Results from the VERITAS study 2014
2014 Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction 2014
2014 Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failure 2014
2014 Conversion from sildenafil to tadalafil: Results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study 2014
2014 Digoxin use and lower 30-day all-cause readmission for medicare beneficiaries hospitalized for heart failure 2014
2014 Have risk factors for mortality after heart transplantation changed over time? Insights from 19 years of Cardiac Transplant Research Database study 2014
2014 Hemodynamic ranges during daily activities and exercise testing in patients with pulmonary arterial hypertension 2014
2014 Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction 2014
2013 Heart remodeling induced by adjuvant trastuzumab-containing chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2: A prospective study 2013
2013 The relationships among satisfaction with social support, quality of life, and survival 5 to 10 years after heart transplantation 2013
2013 Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure 2013
2013 Effects of exercise on left ventricular systolic and diastolic properties in patients with heart failure and a preserved ejection fraction versus heart failure and a reduced ejection fraction 2013
2013 Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: Results of the randomized IMPRES study 2013
2013 Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension 2013
2013 Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension 2013
2012 Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension 2012
2012 Zygomycosis over-infection during voriconazole therapy for aspergillosis in a heart transplant patient, successfully treated with liposomal amphotericin and posaconazole 2012
2012 Erratum: Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial (The Lancet (2011) 377 (658-666)) 2012
2011 Low risk of intracerebral hemorrhage with adjunctive IIb/IIIa inhibitors in Ad Hoc carotid artery stenting 2011
2011 Systemic oxidative stress and endothelial dysfunction is associated with an attenuated acute vascular response to inhaled prostanoid in pulmonary artery hypertension patients 2011
2011 Total lymphoid irradiation in heart transplantation: Long-term efficacy and survival-an 18-year experience 2011
2011 Continuous Hemodynamic Monitoring in Patients With Mild to Moderate Heart Failure: Results of the Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) Trial 2011
2011 Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure 2011
2011 Hemodynamic factors associated with acute decompensated heart failure: Part 2 - Use in automated detection 2011
2011 Implantable Hemodynamic Monitors 2011
2011 Hemodynamic factors associated with acute decompensated heart failure: Part 1 - Insights into pathophysiology 2011
2011 Safety and accuracy of a wireless pulmonary artery pressure monitoring system in patients with heart failure 2011
2011 Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial 2011
2011 A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure 2011
2011 CHAMPION trial rationale and design: The long-term safety and clinical efficacy of a wireless pulmonary artery pressure monitoring system 2011
2011 Intrapulmonary shunting associated with sildenafil treatment in a patient with idiopathic pulmonary arterial hypertension 2011
2010 Outcomes of the RESTOR-MV trial (Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve) 2010
2010 Chronic ambulatory intracardiac pressures and future heart failure events 2010
2010 Bradycardia and syncope as a presentation of cardiac allograft rejection involving the conducting system 2010
2009 Invasive monitoring in patients with heart failure 2009
2009 Reduction in mitral regurgitation during therapy guided by measured filling pressures in the ESCAPE trial 2009
2009 Safety and Efficacy of Ibutilide in Heart Transplant Recipients 2009
2009 Implantable Hemodynamic Monitors 2009
2008 Application of Implantable Hemodynamic Monitoring in the Management of Patients With Diastolic Heart Failure: A Subgroup Analysis of the COMPASS-HF Trial 2008
2008 Effect of treatment with continuous positive airway pressure or oxygen on sleep-disordered breathing in patients with heart failure: Results of the sleep events, Arrhythmias, and respiratory analysis in chronic heart failure (SEARCH) study 2008
2008 Transition from chronic compensated to acute d compensated heart failure: Pathophysiological insights obtained from continuous monitoring of intracardiac pressures 2008
2008 Effects of continuous aortic flow augmentation in patients with exacerbation of heart failure inadequately responsive to medical therapy: Results of the multicenter trial of the orqis medical cancion system for the enhanced treatment of heart failure unresponsive to medical therapy (MOMENTUM) 2008
2008 Continuous Hemodynamic Monitoring in Patients With Pulmonary Arterial Hypertension 2008
2008 Re-stenosis After Drug-eluting Stents in Cardiac Allograft Vasculopathy 2008
2008 Randomized Controlled Trial of an Implantable Continuous Hemodynamic Monitor in Patients With Advanced Heart Failure. The COMPASS-HF Study 2008
2008 Task Force 8: Training in Heart Failure. Endorsed by the Heart Failure Society of America 2008
2008 A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: Rationale, design, and baseline patient characteristics 2008
2008 Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial 2008
2008 Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension 2008
2007 Comparison of a Radiofrequency-Based Wireless Pressure Sensor to Swan-Ganz Catheter and Echocardiography for Ambulatory Assessment of Pulmonary Artery Pressure in Heart Failure 2007
2007 Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: The VERITAS randomized controlled trials 2007
2007 Rationale, Design, and Methods for a Pivotal Randomized Clinical Trial of Continuous Aortic Flow Augmentation in Patients With Exacerbation of Heart Failure: The MOMENTUM Trial 2007
2007 Reducing events in patients with chronic heart failure (REDUCEhf) study design: Continuous hemodynamic monitoring with an implantable defibrillator 2007
2007 Post-Heart Transplant Diastolic Dysfunction Is a Risk Factor for Mortality 2007
2007 The safety of bivalirudin during elective percutaneous coronary interventions in heart transplant patients 2007
2007 Rationale, design, and methods for the Transplant-Eligible MAnagement of Congestive Heart Failure (TMAC) trial: A multicenter clinical outcomes trial using nesiritide for TMAC 2007
2007 Alterations in the Fibrinolytic Cascade Post-transplant: Evidence of a Bimodal Expression Pattern 2007
2007 A Wireless Pressure Sensor for Monitoring Pulmonary Artery Pressure in Advanced Heart Failure: Initial Experience 2007
2007 A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure: The ACCLAIM trial rationale and design 2007
2007 Right ventricular pressure waveform and wave reflection analysis in patients with pulmonary arterial hypertension 2007
2006 Tissue Doppler assessment of longitudinal right and left ventricular strain and strain rate in pulmonary artery hypertension 2006
2006 Case studies in advanced monitoring with the chronicle® device 2006
2006 Temporal trends and drug exposures in pulmonary hypertension: An American experience 2006
2006 Beta-Blocker Use and Outcomes Among Hospitalized Heart Failure Patients 2006
2006 Utility of Impedance Cardiography for the Identification of Short-Term Risk of Clinical Decompensation in Stable Patients With Chronic Heart Failure 2006
2006 Acute take-off of the right coronary artery with long intra-aortic wall course presenting as chronic coronary ostium occlusion in a patient with end-stage heart failure 2006
2006 Heart failure, chronic diuretic use, and increase in mortality and hospitalization: An observational study using propensity score methods 2006
2006 Implantable hemodynamic monitoring devices in heart failure 2006
2006 Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: Reanalysis of the multicenter trial 2006
2006 Rejection with hemodynamic compromise: Objective evidence for efficacy of photopheresis 2006
2006 Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease 2006
2006 Heart Rhythm Considerations in Heart Transplant Candidates and Considerations for Ventricular Assist Devices: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates-2006 2006
2006 Validation and clinical utility of a simple in-home testing tool for sleep-disordered breathing and arrhythmias in heart failure: results of the Sleep Events, Arrhythmias, and Respiratory Analysis in Congestive Heart Failure (SEARCH) study. 2006
2005 Ultrafiltration: A new approach toward mechanical diuresis in heart failure 2005
2005 Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure 2005
2005 Multi-organ transplantation: Is there a protective effect against acute and chronic rejection? 2005
2005 Post-operative obesity and cachexia are risk factors for morbidity and mortality after heart transplant: Multi-institutional study of post-operative weight change 2005
2005 Trans-telephonic monitoring of continuous haemodynamic measurements in heart failure patients 2005
2005 Tezosentan in patients with acute heart failure: Design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS) 2005
2005 Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients 2005
2005 Thoracic organ transplantation in the United States, 1994-2003 2005
2005 Thoracic organ transplantation in the United States, 1994-2003. 2005
2005 The case for selective re-issuance of medical certificates to allow pilots who have received a heart transplant to resume flying 2005
2005 To induce or not to induce: Do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy? 2005
2004 The impact of arrhythmias in acute heart failure 2004
2004 Palliation of allograft vasculopathy with transluminal angioplasty: A decade of experience 2004
2004 Neurological events during long-term mechanical circulatory support for heart failure: The Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) experience 2004
2004 Long-Term Follow-Up of Brachytherapy for Treatment of Allograft In-Stent Restenosis 2004
2003 Retransplantation in 7,290 primary transplant patients: A 10-year multi-institutional study 2003
2003 Infection in ventricular assist devices: prevention and treatment. 2003
2003 Evolving trends in risk profiles and causes of death after heart transplantation: A ten-year multi-institutional study 2003
2003 Relative perioperative bradycardia does not lead to adverse outcomes after cardiac transplantation 2003
2003 Efficacy and safety of treprostinil: An epoprostenol analog for primary pulmonary hypertension 2003
2002 Is there a need for surveillance endomyocardial biopsies in heart transplantation? 2002
2002 Treatment of end-stage heart disease with outpatient ventricular assist devices 2002
2002 Cardiac transplant patients response to the 31P MRS stress test 2002
2002 Short-term intravenous milrinone for acute exacerbation of chronic heart failure: A randomized controlled trial 2002
2002 BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy 2002
2002 Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial 2002
2002 Intravenous milrinone is no better than standard therapy for people admitted with acute exacerbation of chronic heart failure 2002
2001 Nuggets, pearls, and vignettes of master heart failure clinicians. Part 2-the physical examination. 2001
2001 Cardiac transplant outcome of patients supported on left ventricular assist device vs intravenous inotropic therapy 2001
2001 A multi-institutional study of cardiac retransplantation: incidence, risk factors for mortality, and outcome. 2001
2001 The emergence of co-morbid diseases impacting survival after cardiac transplantation, a ten year multi-institutional experience. 2001
2001 Who is most likely to enjoy long term survival after cardiac transplantation? Risk stratification in a 10 year multi-institutional experience. 2001
2001 Mechanical cardiac support 2000: current applications and future trial design. June 15-16, 2000 Bethesda, Maryland. 2001
2001 Nesiritide: a unique therapeutic cardiac peptide. 2001
2000 Self-report versus performance-based activities of daily living capacity among heart transplant candidates and their caregivers 2000
2000 Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure 2000
2000 Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: A randomized, controlled trial 2000
2000 31P-magnetic resonance spectroscopy studies of cardiac transplant patients at rest 2000
2000 Activities of daily living among heart transplant candidates: Neuropsychological and cardiac function predictors 2000
2000 Biventricular pacing for congestive heart failure: Questions of who, what, where, why, how, and how much 2000
2000 Cost-benefit analysis of extended antifungal prophylaxis in ventricular assist devices 2000
2000 Echocardiographic diagnosis of a stenotic double orifice parachute mitral valve with a single papillary muscle 2000
2000 Psychological defensiveness among heart transplant candidates 2000
2000 Rationale and design of a randomized clinical trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with advanced heart failure: The multicenter InSync randomized clinical evaluation (MIRACLE) 2000
2000 Rationale and design of the OPTIME CHF trial: Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure 2000
2000 Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure. 2000
1999 Nonpharmacologic Validation of the Intrinsic Heart Rate in Cardiac Transplant Recipients 1999
1999 Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: A randomized, multicenter, double-blind comparison with the oil based formulation of cyclosporine - Results at six months after transplantation 1999
1999 Are preoperative obesity and cachexia risk factors for post heart transplant morbidity and mortality: A multi-institutional study of preoperative weight-height indices 1999
1999 [Selection and evaluation of candidate patients for heart transplant]. 1999
1999 Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension 1999
1999 Consensus recommendations for the management of chronic heart failure: Introduction 1999
1999 Effect of inotrope withdrawal on morbidity and mortality in patients with chronic heart failure: Results of the vesnarinone trial withdrawal substudy 1999
1999 Selection and evaluation of patients for cardiac transplantation 1999
1998 A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure 1998
1998 Gene polymorphisms for plasminogen activator inhibitor-1/tissue plasminogen activator and development of allograft coronary artery disease 1998
1998 Noninvasive rejection monitoring of cardiac transplants using high resolution intramyocardial electrograms: Initial US multicenter experience 1998
1998 Heart transplant coronary artery disease detected by coronary angiography: A multiinstitutional study of preoperative donor and recipient risk factors 1998
1998 A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients 1998
1998 Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. 1998
1998 Efficacy of coronary stenting in the management of cardiac allograft vasculopathy 1998
1998 Evaluation of hibernating myocardium in patients with ischemic heart disease 1998
1998 Intrapulmonary shunting in primary pulmonary hypertension: An observation in two patients treated with epoprostenol sodium 1998
1998 Risk of death or incapacitation after heart transplantation, with particular reference to pilots 1998
1997 Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension 1997
1997 Recurrent or persistent cardiac allograft rejection: therapeutic options and recommendations. 1997
1997 Serial measurements of interleukin-6, interleukin-8, tumor necrosis factor-α, and soluble vascular cell adhesion molecule-1 in the peripheral blood plasma of human cardiac allograft recipients 1997
1997 Simultaneous use of an implanted defibrillator and ventricular assist device 1997
1997 Heart transplant rejection with hemodynamic compromise: A multiinstitutional study of the role of endomyocardial cellular infiltrate 1997
1997 The incremental risk of female sex in heart transplantation: A multiinstitutional study of peripartum cardiomyopathy and pregnancy 1997
1997 Ventricular assist devices as a bridge to cardiac transplantation: A prelude to destination therapy 1997
1997 Heart transplant rejection with hemodynamic compromise: a multiinstitutional study of the role of endomyocardial cellular infiltrate. Cardiac Transplant Research Database. 1997
1997 The incremental risk of female sex in heart transplantation: a multiinstitutional study of peripartum cardiomyopathy and pregnancy. Cardiac Transplant Research Database Group. 1997
1997 Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. 1997
1997 Competing outcomes after heart transplantation: A comparison of eras and outcomes 1997
1997 Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension 1997
1997 Heart Transplant Candidates: A Neuropsychological Descriptive Database 1997
1997 Predicting outcome after cardiac transplantations: Lessons from the Cardiac Transplant Research Database 1997
1997 Recurrent or persistent cardiac allograft rejection: Therapeutic options and recommendations 1997
1997 Replacement of an intracorporeal left ventricular assist device 1997
1997 The impact of a defensive response set on the relationship between MMPI and cognitive tests among heart transplant candidates 1997
1996 Secular trends in cardiac transplant recipient and donor management in the United States, 1990 to 1994. A multi-institutional study. Cardiac Transplant Research Database Group. 1996
1996 Risk factors for early, cumulative, and fatal infections after heart transplantation: A multiinstitutional study 1996
1996 A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension 1996
1996 Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation results of a prospective, randomized multicenter trial 1996
1996 Infections during extended circulatory support: University of Alabama at Birmingham experience 1989 to 1994 1996
1996 Secular trends in cardiac transplant recipient and donor management in the United States, 1990 to 1994: A multi-institutional study 1996
1996 Treatment of hyperlipidemia after heart transplantation and rationale for the heart transplant lipid registry 1996
1995 Selection and treatment of candidates for heart transplantation: A statement for health professionals from the committee on heart failure and cardiac transplantation of the council on clinical cardiology, American Heart Association 1995
1995 Acute hemodynamic effects of the prostacyclin analog 15AU81 in severe congestive heart failure 1995
1995 Total lymphoid irradiation in the treatment of early or recurrent heart transplant rejection 1995
1995 Risk factors for late recurrent rejection after heart transplantation: a multiinstitutional, multivariable analysis. Cardiac Transplant Research Database Group. 1995
1995 Safety and efficacy of epoprostenol in patients with severe congestive heart failure 1995
1995 Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group. 1995
1995 Cardiac transplant coronary artery disease: A multivariable analysis of pretransplantation risk factors for disease development and morbid events 1995
1995 Circulatory support for myocardial infarction with ventricular arrhythmias 1995
1995 Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients 1995
1995 Left atrial or ventricular cannulation beyond 30 days for a Thoratec ventricular assist device 1995
1995 Lisinopril Versus Placebo in the Treatment of Heart Failure: The Lisinopril Heart Failure Study Group 1995
1995 Predictors of quality of life in patients with advanced heart failure awaiting transplantation 1995
1995 Predictors of quality of life in patients with advanced heart failure awaiting transplantation. 1995
1995 Risk factors for late recurrent rejection after heart transplantation: A multiinstitutional, multivariable analysis 1995
1995 Utility of posttransplantation panel-reactive antibody measurements for the prediction of rejection frequency and survival of heart transplant recipients 1995
1994 Influence of HLA mismatch on rejection after heart transplantation: a multiinstitutional study. The Cardiac Transplant Research Database Group. 1994
1994 Treatment of recurrent heart rejection with mycophenolate mofetil (RS- 61443): Initial clinical experience 1994
1994 Cytomegalovirus after heart transplantation. Risk factors for infection and death: a multiinstitutional study. The Cardiac Transplant Research Database Group. 1994
1994 Infection after heart transplantation: a multiinstitutional study. Cardiac Transplant Research Database Group. 1994
1994 Matching the heart donor and heart transplant recipient. Clues for successful expansion of the donor pool: a multivariable, multiinstitutional report. The Cardiac Transplant Research Database Group. 1994
1994 Cytomegalovirus after heart transplantation. Risk factors for infection and death: A multiinstitutional study 1994
1994 Infection after heart transplantation: A multiinstitutional study 1994
1994 Influence of HLA mismatch on rejection after heart transplantation: A multiinstitutional study 1994
1994 Influence of longer term left ventricular assist device support on valvular regurgitation 1994
1994 Invited letter concerning: Acute interstitial nephritis in a cardiac transplant recipient receiving ciprofloxacin 1994
1994 Matching the heart donor and heart transplant recipient. Clues for successful expansion of the donor pool: A multivariable, multiinstitutional report 1994
1994 Ventricular assist: experience with a pulsatile heterotopic device. 1994
1993 Influence of left ventricular assist on valvular regurgitation. 1993
1993 Total lymphoid irradiation: is there a role in pediatric heart transplantation? 1993
1993 Pretransplantation risk factors for death after heart transplantation: a multiinstitutional study. The Transplant Cardiologists Research Database Group. 1993
1993 Pretransplantation risk factors for acute rejection after heart transplantation: a multiinstitutional study. The Transplant Cardiologists Research Database Group. 1993
1993 Long-term function of cryopreserved aortic homografts: A ten-year study 1993
1993 Pretransplantation risk factors for acute rejection after heart transplantation: A multiinstitutional study 1993
1993 Pretransplantation risk factors for death after heart transplantation: A multiinstitutional study 1993
1993 Task force 4: Function of the heart trnsplant recipient 1993
1993 Use of expanded polytetrafluoroethylene pericardial substitute with ventricular assist devices 1993
1992 Methotrexate pulse therapy in the treatment of recurrent acute heart rejection 1992
1992 Rejection after cardiac transplantation. A time-related risk factor analysis. 1992
1992 Cyclosporine blood monitoring after heart transplantation: a prospective comparison of monoclonal and polyclonal radioimmunoassays. 1992
1992 Renal, hemodynamic, and electrocardiographic effects of low versus high osmolality contrast agents on the transplanted heart. 1992
1992 Application of Echocardiographic Color Flow Doppler Mitral Regurgitation to the Diagnosis of Acute Cardiac Transplant Rejection 1992
1992 Assessment of global and regional left ventricular performance at rest and during exercise after thrombolytic therapy for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) II study 1992
1992 Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure: Results of a multicenter trial 1992
1992 Cardiac transplantation: Recipient selection, donor procurement, and medical follow-up: A statement for health professionals from the Committee on Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association 1992
1992 Coronary angioplasty in cardiac transplant patients: Results of a multicenter study 1992
1992 Cyclosporine blood monitoring after heart transplantation: A prospective comparison of monoclonal and polyclonal radioimmunoassays 1992
1992 Cytomegalovirus Colitis Presenting as Hematochezia and Requiring Resection 1992
1992 Renal, hemodynamic, and electrocardiographic effects of low versus high osmolality contrast agents on the transplanted heart 1992
1992 Total lymphoid irradiation in the treatment of early or recurrent heart rejection 1992
1991 Case report: Circulatory support for seventy days with resolution of acute heart failure [2] 1991
1991 Long-term effect of thrombolytic therapy on left ventricular ejection fraction after acute myocardial infarction 1991
1991 Diltiazem-cyclosporine interaction in cardiac transplant recipients: impact on cyclosporine dose and medication costs. 1991
1991 Analysis and predictors of pulmonary vascular resistance after cardiac transplantation 1991
1991 Diltiazem-cyclosporine interaction in cardiac transplant recipients: Impact on cyclosporine dose and medication costs 1991
1990 Gastrointestinal complications after cardiac transplantation. Potential benefit of early diagnoses and prompt surgical intervention 1990
1990 Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3 1990
1990 Transesophageal Echocardiographic Evaluation of Mechanical Biventricular Assist Device 1990
1989 Arrhythmias after orthotopic cardiac transplantation. Prevalence and determinants during initial hospitalization and late follow-up. 1989
1989 Variables predictive of good functional outcome following thrombolytic therapy in the Thrombolysis in Myocardial Infarction phase II (TIMI II) pilot study 1989
1989 Arrhythmias after orthotopic cardiac transplantation. Prevalence and determinants during initial hospitalization and late follow-up 1989
1989 Coronary artery to right ventricle fistula in heart transplant recipients: A complication of endomyocardial biopsy 1989
1988 Synergistic nephrotoxicity due to ciprofloxacin and cyclosporine. 1988
1988 Pulmonary vascular resistance and the risk of heart transplantation 1988
1988 Synergistic nephrotoxicity due to ciprofloxacin and cyclosporine 1988
1987 Thrombolytic therapy in acute myocardial infarction. 1987
1986 Have the results of mitral valve replacement improved? 1986

Chapter

Year Title Altmetric
2008 Role of left ventricular assist devices in acute heart failure syndrome and the future of the replacement heart.  737-747. 2008

Principal Investigator On

  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION 2016 - 2026
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION 2016 - 2026
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION 2019 - 2023
  • Private Grant  awarded by MEDTRONIC, INC. 2011 - 2023
  • Private Grant  awarded by LUNG BIOTECHNOLOGY PBC 2018 - 2022
  • Private Grant  awarded by Actelion Pharmaceuticals Ltd. 2018 - 2019
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION 2019
  • Private Grant  awarded by LUNG BIOTECHNOLOGY PBC 2018 - 2019
  • Private Grant  awarded by LUNG BIOTECHNOLOGY PBC 2013 - 2019
  • Private Grant  awarded by BELLEROPHON PULSE TECHNOLOGIES LLC 2016 - 2018
  • Private Grant  awarded by Actelion Pharmaceuticals Ltd. 2010 - 2017
  • Private Grant  awarded by Actelion Pharmaceuticals Ltd. 2006 - 2016
  • Private Grant  awarded by INO THERAPEUTICS, INC. 2013 - 2016
  • Private Grant  awarded by ZEALAND PHARMA 2006 - 2016
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION 2009 - 2016
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION 2008 - 2016
  • Private Grant  awarded by Gilead Sciences 2011 - 2016
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION 2011 - 2015
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2010 - 2015
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION 2008 - 2014
  • Private Grant  awarded by Gilead Sciences 2010 - 2014
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION 2009 - 2014
  • Private Grant  awarded by Pfizer Pharmaceuticals 2009 - 2014
  • Private Grant  awarded by Pfizer Pharmaceuticals 2009 - 2014
  • Private Grant  awarded by Pfizer Pharmaceuticals 2009 - 2014
  • Private Grant  awarded by ACTELION CLINICAL RESEARCH, INC. 2009 - 2014
  • Private Grant  awarded by ACTELION CLINICAL RESEARCH, INC. 2009 - 2014
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2010 - 2013
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION 2011 - 2013
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION 2008 - 2013
  • Private Grant  awarded by MEDTRONIC, INC. 2010 - 2013
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2009 - 2013
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION 2010 - 2013
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION 2008 - 2013
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION 2012 - 2013
  • Private Grant  awarded by GENO LLC 2010 - 2013
  • Private Grant  awarded by ELI LILLY AND COMPANY 2010 - 2013
  • Private Grant  awarded by Bayer AG 2010 - 2012
  • Private Grant  awarded by Bayer AG 2010 - 2012
  • Private Grant  awarded by Bayer AG 2010 - 2012
  • Private Grant  awarded by Bayer AG 2010 - 2012
  • Private Grant  awarded by GENO LLC 2010 - 2012
  • Mechanisms of B Cell Responses in Autoimmune Disease: A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituxibab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)  awarded by Duke University 2010 - 2012
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION 2009 - 2012
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2009 - 2012
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2010 - 2011
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION 2009 - 2011
  • Private Grant  awarded by MEDTRONIC, INC. 2003 - 2011
  • Private Grant  awarded by MEDTRONIC, INC. 2008 - 2011
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION 2008 - 2011
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2009 - 2011
  • Private Grant  awarded by MEDTRONIC, INC. 2003 - 2011
  • Private Grant  awarded by HESPERION USA, INC. 2007 - 2009
  • Investigator On

  • Private Grant  awarded by EIGER BIOPHARMACEUTICALS, INC. 2016 - 2026
  • Private Grant  awarded by LUNG BIOTECHNOLOGY PBC 2019 - 2024
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION 2019 - 2023
  • Private Grant  awarded by ARENA PHARMACEUTICALS, INC. 2019 - 2023
  • Private Grant  awarded by COMPLEXA, INC. 2018 - 2022
  • Private Grant  awarded by LIVANOVA USA, INC. 2018 - 2022
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2016 - 2022
  • Private Grant  awarded by EIGER BIOPHARMACEUTICALS, INC. 2016 - 2021
  • Private Grant  awarded by HEARTWARE, INC. 2014 - 2021
  • Sustaining Quality of Life of the Aged: Heart Transplant or Mechanical Support  awarded by Northwestern University 2015 - 2020
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION 2017 - 2019
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION 2017 - 2019
  • Private Grant  awarded by HEARTWARE, INC. 2010 - 2019
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2017 - 2019
  • Private Grant  awarded by AASTROM BIOSCIENCES, INC. 2013 - 2018
  • Private Grant  awarded by Pfizer Pharmaceuticals 2014 - 2018
  • Treatment of Preserved Cardiac Function Heart Failure with an Aldosterine Antagonist (TOPCAT)  awarded by NEW ENGLAND RESEARCH INSTITUTE 2007 - 2017
  • Private Grant  awarded by SUNSHINE HEART, INC. 2009 - 2016
  • Private Grant  awarded by ARENA PHARMACEUTICALS, INC. 2014 - 2016
  • Private Grant  awarded by ARENA PHARMACEUTICALS, INC. 2014 - 2016
  • Private Grant  awarded by EVAHEART, INC. 2011 - 2016
  • Private Grant  awarded by SUNSHINE HEART, INC. 2013 - 2016
  • Private Grant  awarded by BIOCONTROL MEDICAL 2013 - 2016
  • Private Grant  awarded by PARACOR MEDICAL, INC. 2010 - 2015
  • Private Grant  awarded by PARACOR MEDICAL, INC. 2010 - 2015
  • Private Grant  awarded by Actelion Pharmaceuticals Ltd. 2013 - 2015
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2004 - 2015
  • Private Grant  awarded by CARDIOVASCULAR CLINICAL SCIENCE FOUNDATION 2012 - 2015
  • Private Grant  awarded by CARDIOMEMS, INC. 2007 - 2014
  • Private Grant  awarded by ACORN CARDIOVASCULAR, INC. 2008 - 2014
  • Private Grant  awarded by GAMBRO HEALTHCARE 2013 - 2014
  • A Randomized, Controlled Phase 1 Study of External Counterplusation as a Treatment for Acute Ischemic Stoke - (CUFFS)  awarded by University of California, San Diego 2009 - 2014
  • Long Term Outcome Follow-Up of the RAD001 B253 Study, Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients  awarded by Cedars - Sinai Medical Center 2013 - 2014
  • Private Grant  awarded by Bayer AG 2010 - 2014
  • Private Grant  awarded by Actelion Pharmaceuticals Ltd. 2010 - 2014
  • Private Grant  awarded by CARDIOMEMS, INC. 2007 - 2013
  • Private Grant  awarded by St. Jude Medical 2013
  • Private Grant  awarded by Gilead Sciences 2010 - 2013
  • Private Grant  awarded by Gilead Sciences 2008 - 2013
  • Private Grant  awarded by SYNVISTA THERAPEUTICS, INC. 2008 - 2013
  • Genomic Classification of the Heart Transplant Endomyocardial Biopsy  awarded by University of California, Los Angeles 2012 - 2013
  • Genomic Classification of the Heart Transplant Endomyocardial Biopsy  awarded by American Heart Association (Southeast Affiliate) 2011 - 2013
  • Private Grant  awarded by Actelion Pharmaceuticals Ltd. 2008 - 2013
  • Private Grant  awarded by LILLY-ICOS, LLC 2006 - 2013
  • Private Grant  awarded by VENTRACOR, INC. 2007 - 2012
  • Private Grant  awarded by VENTRACOR, INC. 2007 - 2012
  • Private Grant  awarded by SYNVISTA THERAPEUTICS, INC. 2008 - 2012
  • Private Grant  awarded by Gilead Sciences 2008 - 2012
  • Private Grant  awarded by TERUMO HEART, INC 2009 - 2012
  • Private Grant  awarded by CARDIOXYL PHARMACEUTICALS, INC. 2010 - 2011
  • Teaching Activities

  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2011) 2011
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2011) 2011
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2011) 2011
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2011) 2011
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2011) 2011
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2011) 2011
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2011) 2011
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2011) 2011
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2011) 2011
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2011) 2011
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2011) 2011
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2011) 2011
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2011) 2011
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2011) 2011
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2011) 2011
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2011) 2011
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2011) 2011
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2010) 2010
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2010) 2010
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2010) 2010
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2010) 2010
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2010) 2010
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2010) 2010
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2010) 2010
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2010) 2010
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2010) 2010
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2009) 2009
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2009) 2009
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2009) 2009
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2009) 2009
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2009) 2009
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2009) 2009
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2009) 2009
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2009) 2009
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2009) 2009
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2008) 2008
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2008) 2008
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2008) 2008
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2008) 2008
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2008) 2008
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2008) 2008
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2008) 2008
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2008) 2008
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2008) 2008
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2007) 2007 - 2008
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2007) 2007
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2007) 2007
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2007) 2007
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2007) 2007
  • 28-434 - CARDIOLOGY CONSULT (Fall Term 2007) 2007
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2007) 2007
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2007) 2007
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2007) 2007
  • 28-434 - CARDIOLOGY CONSULT (Spring Term 2007) 2007
  • Education And Training

  • Doctor of Medicine, Louisiana State University Health Sciences Center - New Orleans 1979
  • UAB Hospital, Internship 1980
  • UAB Hospital, Residency 1982
  • UAB Hospital, Postdoctoral Fellowship 1984
  • Full Name

  • Robert Bourge